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Background: 6-Shogaol is a promising antitumor agent isolated from dietary ginger (Zingiber officinale). However,
little is known about the efficacy of 6-shogaol on leukemia cells. Here we investigated the underlying mechanism
of 6-shogaol induced apoptosis in human leukemia cells in vitro and in vivo.
Methods: Three leukemia cell lines and primary leukemia cells were used to investigate the apoptosis effect of
6-shogaol. A shotgun approach based on label-free proteome with LC-CHIP Q-TOF MS/MS was employed to
identify the cellular targets of 6-shogaol and the differentially expressed proteins were analyzed by bioinformatics
protocols.
Results: The present study indicated that 6-shogaol selectively induced apoptosis in transformed and primary
leukemia cells but not in normal cells. Eukaryotic translation initiation factor 2 alpha (eIF2α), a key regulator in
apoptosis signaling pathway, was significantly affected in both Jurkat and U937 proteome profiles. The docking
results suggested that 6-shogaol might bind well to eIF2α at Ser51 of the N-terminal domain. Immunoblotting data
indicated that 6-shogaol induced apoptosis through a process involving dephosphorylation of eIF2α and caspase
activation–dependent cleavage of eIF2α. Furthermore, 6-shogaol markedly inhibited tumor growth and induced
apoptosis in U937 xenograft mouse model.
Conclusion: The potent anti-leukemia activity of 6-shogaol found both in vitro and in vivo in our study make this
compound a potential anti-tumor agent for hematologic malignancies.
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In recent years, the use of natural dietary agents has be-
come widely accepted as a realistic option for the treatment
of malignant cancers because of their cost-effectiveness and
wide safety margin. 6-Shogaol, a major pungent ingredient
in ginger (Zingiber officinale Roscoe, Zingiberaceae), has
attracted great attention due to its considerable pharma-
cologic effects including anti-cancer, anti-inflammatory,
antioxidant, as well as antiemetic properties [1-4]. Eviden-
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reproduction in any medium, provided the orapoptosis in a variety of cancer cells including human lung
cancer, colorectal carcinoma, hepatocarcinoma, ovarian
cancer and breast cancer cells [5-10].
Previous studies on the role of signaling cascades in 6-
shogaol-related lethality have primarily focused on reactive
oxygen species (ROS) production, activation of caspase,
GADD 153 expression, tubulin polymerization, AKT/
mTOR and matrix metalloproteinase 9 (MMP-9) expres-
sion [5,6,9,11]. The compound was also reported to inhibit
breast cancer cell invasion by reducing MMP-9 expression
via targeting the NF-kB activation cascade [9] or by inhib-
iting invade podium formation [12]. Our group and Gan
et al. have found that 6-shogaol induced G2/M cell cycle
arrest and apoptosis characterized by caspase 3 and PARP
cleavage in HeLa and HCT116 cells [3,13]. Despite enor-
mous efforts performed to investigate the anticancerThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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apoptosis induced by 6-shogaol in human leukemia cells
has not yet been explored, nor have the relationships
between 6-shogaol-mediated anti-leukemic activity and cell
signaling cascades been examined in depth.
Cell apoptosis involves two distinct pathways, the death
receptor-initiated extrinsic pathway and the mitochondria-
mediated intrinsic pathway [14,15]. Recent studies point to
endoplasmic reticulum (ER) as a third subcellular compart-
ment implicated in apoptotic execution [16,17]. Disruption
of any function of ER causes ER stress and activates a
cytoprotective signaling cascade called unfolded protein
response (UPR) [18]. Different stimuli signal through
several protein kinases to up-regulate the protein folding
capacity of the ER through UPR induces the expression of
ER chaperones such as GRP78/BiP [19]. Nowadays, the
proteomic platform represents a powerful tool for profiling
the comprehensive protein expression and investigation of
the apoptotic mechanism of drugs. In particular the shot-
gun approach by label-free LC-CHIP Q-TOF MS/MS
allows the qualitative and quantitative analysis of complex
samples.
In the present study, we examined the apoptotic
effects of 6-shogaol on three different leukemia cell lines
and primary leukemia patients cells. A shotgun proteo-
mics strategy based on LC-CHIP Q-TOF MS/MS was
used to identify and quantify the differentially-expressed
proteins of control and 6-shogaol-treated leukemia cells.
Our results showed that cleavage of eIF2α and phospho-
eIF2α by caspase activation may contribute to 6-shogaol-
mediated cell death in human leukemia cells. Our in vivo
results indicate that induction of apoptosis may contribute
to 6-shogaol-mediated inhibitory effects on tumor growth
of U937 xenograft mouse model. These findings provide a
novel mechanistic basis for 6-shogaol as a leukemia treat-
ment strategy.
Results
6-Shogaol potently induced apoptosis in transformed and
primary human leukemia cells, but not in normal bone
marrow mononuclear cells
Flow cytometry analysis revealed that treating Jurkat
cells with 2.5 and 5 μM 6-shogaol for 24 h resulted in a
moderate increase in apoptosis. These events became
apparent at 10 μM and very extensive at 15 μM concen-
trations (Figure 1a). A time-course study of cells exposed
to 15 μM 6-shogaol revealed a moderate increase in
apoptosis as early as 6 h after drug exposure. These
events became apparent after 12 h of drug exposure and
reached near-maximal levels after 24 h of drug exposure
(Figure 1b). Consistent with these findings, the same 6-
shogaol concentrations and exposure intervals caused
cleavage/activation of caspase-3 and caspase-7, as well as
PARP degradation (Figure 1c).To determine whether these events were restricted to
myeloid leukemia cells, parallel studies were performed
in other leukemia cell lines including U937 and HL-60
leukemia cells. These cells exhibited apoptotic effects of 6-
shogaol similar to those observed in Jurkat cells (Figure 1d).
Also, U937 and HL-60 cells caused comparable degrees of
caspase-7 and caspase-3 activation and PARP degradation
(Figure 1e).
To determine whether 6-shogaol could also trigger
apoptosis in primary human leukemia cells, primary
leukemia cells isolated from 7 leukemia patients were
treated without or with 10 and 20 μM 6-shogaol for
24 h, after which apoptosis were determined by Annexin
V/PI staining and flow cytometry. Exposure of cells to 6-
shogaol resulted in pronounced increase in apoptosis in
primary leukemia peripheral blood mononuclear cells
(Figure 1f ). In contract, the 6-shogaol regimen had no
or little effect on apoptosis in normal bone marrow
mononuclear cells (Figure 1g). Together, these findings
indicate that 6-shogaol selectively kills transformed
and primary human leukemia cells but not normal
hematopoietic cells.
Proteins alternation of leukemia cells in response to
6-shogaol treatment by LC-CHIP Q-TOF MS/MS
To get insights into the mechanism of apoptosis induced
by 6-shogaol, an integrated proteomic-bioinformatics
platform was used to investigate the global protein
profiles of control and 6-shogaol-treated leukemia cells.
In order to highlight the main proteome alterations in
leukemia cells in response to 6-shogaol exposure, we
generated protein expression profiles of two cell lines
(Jurkat and U937) by a label-free shotgun proteomic
approach after 12 h treatment with vehicle control (0.1%
DMSO) or 15 μM 6-shogaol. The average peptide spec-
tral intensity was used as a standard to normalize and
compare the relative protein abundance in control and
6-shogaol treated cells [20,21]. More than 800 proteins
were identified in our experiments. The identification of
proteins with remarkable differences (up- or down-
regulated over 2.0-fold) in Jurkat and U937 cells were
shown in Additional file 1: Table S1 and Additional file
2: Table S2. The regulated proteins were listed by their
protein name, accession number of SWISSPROT, abbre-
viations, MW/pI and fold change.
In the present study, all significantly modulated pro-
teins were functionally categorized using the PANTHER
Classification System (http://pantherdb.org) (As indica-
ted in Figure 2a and 2b), the majority of differentially
expressed proteins identified were in the categories of
binding, catalytic activity, structural molecule activity,
enzyme regulator activity and transcription regulator
activity in both Jurkat and U937 cells. We also note that
some differentially expressed proteins in the categories
Figure 1 6-Shogaol induces apoptosis in transformed and primary leukemia cells. Cells apoptosis was determined using Annexin V/PI
staining by flow cytometry. The values obtained from Annexin V/PI represent the mean±SD for three separate experiments. The difference were
significant at *p < 0.05, **p < 0.01. (a) Jurkat cells were treated without or with various concentrations of 6-shogaol (6S) for 24 h. (b) Jurkat cells
were treated without or with 15 μM for different time intervals as indicated. (c) Jurkat cell were treated without or with 6S for various concentra-
tions or time intervals as indicated, total cellular extracts were prepared and subjected to western blot assay using antibodies against PARP,
cleaved-caspase 3 (C-Caspase 3) and cleaved-caspase 7 (C-Caspase 7). (d and e) Jurkat, U937, and HL-60 cells were treated without or with 15 μM
for 24 h, after which apoptosis was determined by flow cytometry. Total cellular extracts of protein were prepared and subjected to western blot
using antibodies as indicated. (f) Mononuclear cells were isolated from the peripheral blood of 7 patients with leukemia (designated as P1–7),
including 4 AML, 1 MM (P7), and 2 CLL patients (P3 and P4). Cells were then treated without or with 10 and 20 μM 6S for 24 hours. (g) Mono-
nuclear cells were isolated from the peripheral blood of 5 healthy donors and incubated with 0, 10 and 20 μM of 6S for 24 hours.
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observed U937 cells.
To validate the proteome data, we used Western blot
to assess the expression of three proteins (Vimentin,
DDX1 and Cathepsin D) with higher fold change values,
which were randomly selected from the list of 33 candi-
dates based on their biologic interest, molecular weight,
and antibody availability (Figure 2c). The data matched
well with the differences exhibited in the proteome ana-
lysis (Figure 2d), which demonstrated the reliability of
the proteomic analysis.
To further understand the biological pathway involved
in 6-shogaol regulated proteins, the PANTHER Classifica-
tion System was used to categorize these proteins accord-
ing to their biological processes. The results demonstrated
that the 6-shogaol-regulated proteins could be classified
into 24 pathways (Figure 3). Among which, four pathways
including apoptosis, Parkinson, ubiquitin proteasome andintegrin signaling were found to be involved in both Jurkat
and U937 cell lines after 6-shogaol treatment. More differ-
entially expressed proteins were found to be associated
with the apoptosis signaling pathway only in 6-shogaol-
treated Jurkat cells. While in 6-shogaol-treated U937 cells,
more significantly modulated proteins were involved in
the ubiquitin proteasome pathway. Also, three proteins,
including GRP78/BiP, CYCS and EIF2S1, were found to be
involved in the regulation of apoptosis in Jurkat cells,
while EIF2S1 and AIFM1 were associated with apoptosis
in U937 cell line.
PERK-eIF2α cross-talk involved in 6-shogaol regulated
apoptotic proteins
In the proteomics analyses, a total of 33 and 81 signifi-
cantly modulated proteins were identified in 6-shogaol-
treated Jurkat and U937 cell lines, respectively. Among
them, six proteins including CTSD, EIF2S1, SSRP1, ILF3,
Figure 2 Functional classification and validation of the differentially expressed proteins. The changed proteins identified by LC-CHIP
Q-TOF MS/MS for Jurkat (a) and U937 cells (b) were characterized according to their molecular functions by PANTHER Classification System.
(c) Jurkat cells were treated with or without 6S (15 μM) for 12 h, and whole-cell lysates were obtained and subjected to western blot analysis
using antibodies against Vimentin, DDX1, Cathepsin D and β-actin. Each blot is the representative result of three independent experiments.
(d) The comparison of fold changes between proteins identified by mass spectrometry and proteins validated by western blot.
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Additional file 2: Table S2) were found to be altered in
both cell lines (Figure 4a). EIF2S1, a key regulator in apop-
tosis signaling pathway (Figure 4a), may play a critical role
in 6-shogaol-mediated lethality in leukemia cells.
To explore the interaction effect of 6-shogaol molecule
to EIF2S1 (eIF2α), an in silico molecular docking study
was performed. We docked 6-shogaol with the two
main parts of eIF2α, C-terminal domain and N-terminalFigure 3 Biological pathways associated with modulated proteins ide
and U937 cells were characterized according to their biological pathway by
shown as red bars indicate the number of U937 cell modulated proteins an
number of all modulated proteins. The blue bars indicate the corresponding
shown are with a p-value < 0.05.domain, separately [22]. Only those regions with binding
energy < −5.0 kcal/mol were chosen as the “Potential
Targets” [23]. As shown in Figure 4b (up), the potential
binding sites may be present in the region A, B and
C of eIF2α, since their binding energy was −6.02, −5.57
and −5.18 kcal/mol, respectively. It has been shown that,
eIF2α contains the regulatory phosphorylation site, and a
serine at position 51 in eIF2α is associated with the func-
tion of apoptosis [24]. Interestingly, serine at position 51ntified in U937 and Jurkat cells by proteomic analysis. Both Jurkat
bioinformatics tool PANTHER Classification System. Percentage values
notated to the respective GO biological pathway term divided by the
ratios for the reference data set in Jurkat cells. All biological pathways
Figure 4 Molecular docking analyses and validation by immunoblotting. (a) Venn diagram depicting a comparison between proteins
identified in Jurkat and U937 cell lines. Six proteins including eIF2α, a key regulator in apoptosis signaling pathway, were found to be altered in
both cell lines. (b) The potential ligand-binding sites in eIF2α were analyzed and the most probable binding region are labeled with A, B and C.
The protein is represented with cartoon model (up). 6S might bind to protein eIF2α at residue Ser51 of the N-terminal domain (down). The pro-
tein structure is displayed in ribbon model. (c) Validation of the docking results by three leukemia cell lines Jurkat, U937 and HL-60. Cells treated
with or without 6S (15 μM) for 12 h were subjected to western blot analysis using antibodies against eIF2α and p-eIF2α (Ser 51). β-actin was used
as reference. Each blot is the representative result of three independent experiments.
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terminal domain (Figure 4b (down)). The docking results
indicated that 6-shogaol might bind well to protein eIF2α
at residue Ser51 of the N-terminal domain. To validate
the interaction of 6-shogaol and the protein eIF2α, immu-
noblotting assay of eIF2α and phospho-eIF2α (Ser 51) in
Jurkat, U937 and HL-60 cell lines was applied. The results
indicated that exposure of cells to 6-shogaol resulted in
reduction in levels of eIF2α and the production of its
cleavage fraction (Figure 4c). The levels of phospho-eIF2α
were also decreased and cleaved form of phospho-eIF2α
was observed after treating cells with 6-shogaol. Such
findings suggest that cleavage and dephosphorylation of
eIF2α may contribute to 6-shogaol-mediated apoptosis in
leukemia cells.
Dephosphorylation and cleavage of eIF2α are required
for 6-shogaol-induced apoptosis
Protein alterations including protein synthesis, folding
and chaperones related to ER stress promoted us to
further investigate the role of ER stress pathway in 6-
shogaol-induced apoptosis. Since UPR is an important
genomic response to ER stress [25], the effects of 6-
shogaol were examined in relation to UPR. Treatment of
cells with 6-shogaol resulted in marked increase in levels
of UPR targets GRP78/Bip and GRP94 in dose- and
time-dependent manners (Figure 5a). Modest increase inlevels of phospho-PERK and phospho-eIF2α after 2 h
and 4 h of drug exposure was observed, and their
normal forms were decreased after 6 h and 12 h of drug
exposure (Figure 5a). Interestingly the cleaved forms of
eIF2α and phospho-eIF2α were noted during the late
time period of 6-shogaol treatment (Figure 5a). Similarly,
the levels of GADD153/CHOP were increased at early
time points of 6-shogaol exposure and then decreased at
late time points of drug exposure (Figure 5a). In con-
trast, 6-shogaol had little or no effect on expression of
ATF6, IRE1 and phospho-IRE1. Taken together, these
findings demonstrate that PERK-eIF2α related ER stress
pathway could play an important role in 6-shogaol-
induced apoptosis in leukemia cells.
6-Shogaol-induced cleavage of eIF2α is dependent on
caspase activation
During apoptosis, a class of cysteine proteases called
caspases act as effectors of the cell death programme [26].
One mechanism by which caspases promote apoptosis is
through cleavage and subsequent activation of protein
kinases [27]. To observe whether 6-shogaol-induced cleav-
age of eIF2α and phospho-eIF2α is dependent on caspase
activation, the pan-caspase inhibitor Z-VAD-fmk was
used. Addition of Z-VAD-fmk blocked 6-shogaol-induced
cell apoptosis and PARP degradation (Figure 5b and 5c).
Interestingly, cleavage of eIF2α and dephosphorylation of
Figure 5 Analysis eIF2α associated ER stress pathway related proteins in the effect of 6S induced apoptosis in Jurkat cells. (a) Jurkat
cells were treated with 15 μM of 6S for 0, 2, 4, 6, and 12 h or treated with various concentrations of 6S as indicated for 6 h. The total cellular
extracts were subjected to western blot assay. β-actin was used as a loading control. Each blot is the representative result of three independent
experiments. (b) Jurkat cells were pretreated with the caspase inhibitor Z-VAD-fmk (20 μM) for 1 h followed by treatment with 15 μM 6S for 12 h.
Apoptosis was determined using flow cytometry. The graph shown represents the mean ± SD. for three separate experiments. The difference
were significant at **p < 0.01. (c) Jurkat cells were treated with vehicle (DMSO 0.1%, v/v) alone or 6S (15 μM) or Z-VAD-fmk (20 μM) or the
combination of 6S and Z-VAD-fmk for 12 h, western blot assay showed that Z-VAD-fmk markedly reduce 6S-induced apoptosis. Each blot is the
representative result of three independent experiments. (d) Jurkat cells were treated with vehicle (DMSO 0.1%, v/v) alone or 6S (15 μM) or Sal (5
μM) or the combination of 6S and Sal for 12 h, cells were stained with Annexin V/PI, and the percentage of apoptotic cells was determined using
flow cytometry. The graph shown represents mean ± SD for three separate experiments. The difference were significant at **p < 0.01. (e) Jurkat
cells were treated with vehicle (DMSO 0.1%, v/v) alone or 6S (15 μM) or Sal (5 μM) or the combination of 6S and Sal for 12 h. Western blot assay
showed that Sal potentiates 6S to induce Jurkat cells apoptosis through maintain the hyperphosphorylated state of eIF2α.
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inhibitor Z-VAD-fmk (Figure 5c). Such findings indicate
that 6-shogaol-mediated caspase activation may be invol-
ved in 6-shogaol-induced cleavage of eIF2α and dephos-
phorylation of PERK.Salubrinal synergizes with 6-shogaol to induce apoptosis
through cleavage of eIF2α
Recent studies showed that eIF2α phosphorylation is
required for cell survival, and inhibition of eIF2α phos-
phorylation enhanced cell death [28,29]. Salubrinal selec-
tively blocks dephosphorylation of eIF2α and protects
cells against ER stress-mediated apoptosis [30,31]. Thus
we tested whether salubrinal could protect Jurkat cells
against 6-shogaol-induced apoptosis. At a dose of 5 μM,
salubrinal had no effect on apoptosis (Figure 5d), despite
inducing eIF2α phosphorylation (Figure 5e). Unexpectedly,co-administration of salubrinal significantly enhanced 6-
shogaol-mediated apoptosis (Figure 5d). As mentioned
above, treating with salubrinal alone resulted in increased
phosphorylation of eIF2α at 12 h. However, combined
treatment of cells with 6-shogaol and salubrinal for 12 h
did not further enhance eIF2α phosphorylation but resul-
ted in pronounced cleavage of eIF2α. Such findings are
consistent with the above results that 6-shogaol-mediated
cleavage of eIF2α is dependent on caspase activation.6-Shogaol inhibits tumor growth of U937 xenograft
mouse model by striking induction of apoptosis
The ability of 6-shogaol in killing human leukemia cells
in vitro led us to evaluate its antileukemic activity
in vivo. Of the leukemia cell lines tested, only the sub-
cutaneous inoculation of U937 cells into NOD/SCID
nude mice resulted in a tumor formation at the site of
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human U937 cells was used in the present study. As
shown in Figure 6b, treatment of mice with 50 mg/kg 6-
shogaol resulted in a modest but significant suppression
of tumor growth 11 days and 14 days following drug
exposure (p < 0.05 vs vehicle control). These events
became more apparent 17 days and 20 days and very
extensive 24 days after drug exposure (p < 0.01 vs vehicle
control) (Figure 6b). However, no significant changes in
weight or other signs of potential toxicity were observed
during the treatment with 6-shogaol (Figure 6c). We
then examined the morphological changes and induction
of apoptosis in tumor section of U937 xenografts using
H&E staining and TUNEL assay. The sections of U937
xenografts from mice treated with 6-shogaol exhibited a
reduced number of cancer cells, with signs of necrosis
with infiltration of inflammatory cells and fibrosis
(Figure 6d, top panels). Exposure to 6-shogaol resulted
in a striking induction of apoptosis in tumor cells, with
signs of numerous dark brown colored apoptotic cells
(Figure 6d, bottom panels). Such findings suggest that 6-Figure 6 6S markedly inhibits tumor growth and induces apoptosis in
mice were injected subcutaneously with 2.5 × 106 U937 cells into the right
(7 mice per group) and treated group (7 mice per group, 6S of 50 mg/kg/d
were conducted as described in the method of murine model. The 6S sign
tumor volume size (b). Data are means ± SD. Values of tumor volume for 6
for the control group by Student’s t-test; *p < 0.05, **p < 0.01. The change o
TUNEL (× 400) assay shows increased numbers of apoptotic cells in the 6S
drug exposure. Tumors were fixed and stained with hemtoxylin and eosin
determine apoptosis.shogaol-mediated antileukemic activity in vivo is associ-
ated with induction of apoptosis.
Discussion
In the present study, we demonstrate that 6-shogaol
selectively induces apoptosis in diverse human leukemia
cell lines as well as in primary human AML blast cells in
dose- and time-dependent manners. However, 6-shogaol
displayed less toxicity on normal human peripheral blood
mononuclear cells, suggesting it may serve as a potentially
valuable candidate for cancer chemotherapy.
For a comprehensive analysis of the molecular targets
of 6-shogaol, we used the label free proteomics scheme
by LC-CHIP Q-TOF MS/MS to identify the differentially
expressed proteins in Jurkat and U937 leukemia cells
after exposure to 6-shogaol. A total of 34 proteins whose
expressions were significantly changed (over two folds)
under 6-shogaol treatment were identified and quanti-
fied (see Additional file 1: Table S1 and Additional file 2:
Table S2). Briefly, based on the protein function analysis,
these 34 proteins could be generally classified into fourthe xenograft animal model. Five- to six-week-old NOD/SCID nude
flank. From the fifth day, mice were randomized into a control group
ay). Intraperitoneal administration of 6S and tumor volume assessment
ificantly inhibits tumor growth (a), which is further confirmed by the
S treatment groups were significantly decreased compared with those
f body weight is shown in (c). Compared with the control group,
treatment group (d). Tumors were obtained from animals 20 days after
(H&E) stain to examine tumor cell morphology, using TUNEL assay to
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olism; (iii) cell death; and (iv) cell cytoskeleton structure. It
must be noted that some proteins may have multiple func-
tions and play roles in more than one pathway.
We have been interested in the mechanisms by which
Jurkat cells recognize stress signals and regulate pro-
grams of gene expression designed to induce apoptosis.
Central to cellular stress responses is a family of protein
kinases that phosphorylate the α-subunit of eukaryotic
initiation factor-2 (eIF2α). EIF2α phosphorylation by
upstream kinases, like PERK or GCN2, can induce cell
growth arrest or apoptosis in response to ER stress
[32,33]. In cell apoptosis, the role of eIF2α phosphoryl-
ation may vary dependent on the cell type and apoptotic
stimulus utilized [34]. Survival and resistance to chemo-
therapy are due to induction of eIF2α phosphorylation
[35]. Otherwise, very intense eIF2α phosphorylation can
activate programmed cell death. In the present report,
we demonstrate that 6-shogaol induces phosphorylation
of PERK and eIF2α at the early time points of drug
exposure. EIF2α phosphorylation is inhibited at the late
stage during apoptosis induced by 6-shogaol. Interest-
ingly, the cleavage of eIF2α and phospho-eIF2α was
induced in various leukemia cell lines during apoptosis
induced by 6-shogaol. It has been reported that eIF2α is a
target for cleavage by caspases upon induction of apop-
tosis in etoposide-treated cells [34]. Only caspase-3 was
capable of eIF2α cleavage, which contributes to regulation
of apoptosis. Consistent with these results, our findings
demonstrate that caspases activation could contribute to
cleavage of eIF2α during 6-shogaol-induced apoptosis
based on the following findings: (i) 6-shogaol induces the
cleavage of eIF2α and phospho-eIF2α at late time points;
(ii) Inhibition of caspase activation by Z-VAD-fmk blocked
6-shogaol-mediated cleavage of eIF2α; (iii) Inhibition of
caspase activation by Z-VAD-fmk also blocked 6-shogaol-
induced apoptosis (Figure 7). Such findings suggest thatFigure 7 Schematic representation of the mechanisms of
6-shogaol in inducing apoptosis in human leukemia cells.the cleavage of eIF2α by caspase activation could contrib-
ute to inhibition or alteration of protein synthesis during
the late stages of apoptosis induced by 6-shogaol.
It has been shown that salubrinal, a selective inhibitor
of cellular complexes that dephosphorylate eIF2α, pro-
tects cells against ER stress-mediated apoptosis [31]. In
our report, salubrinal treatment alone had no effect on
apoptosis in leukemia cells despite inducing eIF2α phos-
phorylation. Unexpectedly, combined treatment of 6-
shogaol with salubrinal for 12 h did not further enhance
eIF2α phosphorylation but resulted in pronounced
cleavage of eIF2α. These results were consistent with the
previous reports that combination of bortezomib with
salubrinal on RPMI 8226 or U266B1 cells resulted in
pronounced cleavage of eIF2a and apoptosis [36]. This
suggests that the combination therapy using 6-shogaol
and salubrinal may be mostly suited for the treatment of
leukemia.
Our previous study has shown that 6-shogaol can
inhibit tumor growth of human hepatocellular xeno-
grafts through the induction of apoptosis [7]. Little is
known, however, about inhibitory effects of 6-shogaol on
tumor growth of human leukemia xenograft model. The
results from in vivo studies demonstrated that 6-shogaol
administration significantly inhibited the tumor growth
of U937 xenograft without causing side effects to the
mice. To understand whether the apoptotic mechanism
in vitro is identical to those in vivo, we next examined
apoptosis in tumor sections using TUNEL staining. A
substantial increase of TUNEL-positive cells was detec-
ted in the 6-shogaol-treated group compared with the
control group, which provides clear evidence for apoptosis
in 6-shogaol-treated U937 xenograft mice. To the best of
our knowledge, this is the first report that describes an
effective extrapolation of the in vitro apoptosis-inducing
effects of 6-shogaol on human leukemia cells to the
in vivo situation.
Conclusion
In summary, the present findings indicate that 6-shogaol
effectively induces cell apoptosis in transformed and
primary human leukemia cells, as well as in leukemia
xenografts. This effect occurs in association with the
cleavage of eIF2α during 6-shogaol-induced apoptosis,
which is dependent on caspase activation. The potent
anti-leukemia activity of 6-shogaol found both in vitro
and in vivo in our study along with the novel mode of
action make this compound a potential anti-tumor or
prevent-tumor agent for hematologic malignancies. In
addition, this work also identifies the cleavage of eIF2α
as a potential biomarker of 6-shogaol-induced apoptosis.
Further efforts are warranted to elucidate the mecha-
nisms by which 6-shogaol induces the cleavage of eIF2α
and to identify other possible factors that contribute to
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vide a better understanding of how this compound
exerts its antitumor activity in vivo and aid in developing
this compound either alone or in combination with
established chemotherapeutic agents to treat leukemia
and potentially other hematologic malignancies.
Methods
Cells and reagents
Human acute T cell leukemia Jurkat, human histiocytic
lymphoma U937 and human acute promyelocytic leukemia
HL-60 cells were obtained from the American Type
Culture Collection (Bethesda, MD, USA). Cells of Jurkat
and U937 were maintained in RPMI-1640 medium with
10% heat-inactivated fetal bovine serum (FBS) in a humid
atmosphere of 5% CO2 at 37°C. Cells of HL-60 were
cultured in IMDM medium, supplemented with 20% FBS,
the other conditions were the same as U937 and Jurkat.
Fresh leukemia mononuclear cells from peripheral blood
of seven leukemia (4 AML, 1 MM and 2 CLL according to
FAB classification system) patients and five healthy donors
were enriched by Ficoll separation. Informed consent was
obtained according to institutional guidelines. Mono-
nuclear cells were suspended in RPMI 1640 medium
containing 10% FBS at a density of approximately 6–8 ×
105/mL for treatment.
6-Shogaol was isolated from Z. officinale in our labora-
tory [37] and its purity was not less than 98% detected
using HPLC. Chemical regents, except for specially
noted, were from Sigma (St. Louis, USA). Antibodies
against PARP, PERK, CHOP, eIF2α, phosphor-eIF2α
(Ser51; p-eIF2α), IRE1α, cleaved caspase-3,-7, and GRP78/
BiP were obtained from Cell signaling Technology (Bev-
erly, MA, USA). Phosphor-PERK (p-PERK) was purchased
from Santa Cruz Biotechnology (CA, USA). Antibodies
against ATF-6, phospho-IRE1α (S724; p-IRE1α), Vimentin,
Cathepsin D, and DDX1 were from Abcam Biotechnology
(Cambridge, UK). Salubrinal, a specific inhibitor of eIF2α-
dephosphorylation, was purchased from Alexis (USA).
Pan-caspase inhibitor of Z-VAD-fmk was from Beyotime
Biotechnology (Beyotime, China). β-actin antibody, horse-
radish peroxidase-conjugated goat anti-mouse IgG, goat
anti-rabbit IgG and rabbit anti-goat IgG were obtained
from Bioss Biotechnology (Bioss, China).
Apoptosis analysis
Apoptosis in cells were measured after treatment with-
out or with 6-shogaol for various concentrations or time
intervals as indicated. The cells were harvest, washed
twice with ice-cold PBS and then determined with
Annexin V-FITC Apoptosis Detection Kit (BD PharMin-
gen, USA) by the manufacturer’s protocol as reported
previously [38]. Analyses were applied on a FACS auto
flow cytometer (BD Biosciences; Mountain View, CA).Both early apoptotic and late apoptotic cells were calcu-
lated in cell death determinations. Each experiment was
performed in triplicate.
Western blot
Cells were lysed in 200 μL WB&IP lysis buffer (1% Triton
X-100) including 1 mM PMSF (Beyotime, China). Protein
extracts (50 μg) were loaded onto a 6-15% polyacrylamide
gel containing SDS, electrophoresed and transferred to
a 0.22 μm nitrocellulose membrane (PALL, USA). The
membranes were blocked with 5% non-fat dried milk in
Tris-buffered saline/0.1% Tween 20 (TBST) and incubated
overnight at 4°C with the appropriate primary antibody.
The blots were washed with TBST three times and then
probed with HRP-conjugated secondary antibodies for 2 h
at room temperature. The immune complexes were visu-
alized using a chemiluminescence phototope-horseradish
peroxidase kit (Pierce, USA) as previously reported [38].
β-actin was used to ensure equivalent loading of whole
cell protein. All the data were confirmed by three individ-
ual experiments.
Shotgun proteomic analysis
The protein preparation, LC-CHIP Q-TOF MS/MS ana-
lysis and data processing were carried out as previously
described [39]. Briefly, 50 μg preparation proteins were
separated by SDS-PAGE. Then the PAGE was stained
with Coomassie brilliant blue G-250 and cut into slices.
Before MS analysis, the gel was destained and dehy-
drated. Then the proteins were digested with trypsin
(10 ng/μL) and 40 mM ammonium bicarbonate/aceto-
nitrile (9:1, v/v) at 37°C water bath overnight. After
digestion, the peptides were extracted with solution
containing 50% acetonitrile and 5% formic acid. The
digested peptides were then concentrated and dried by
speed vac to get lyophilized peptides. HPLC-CHIP
(Agilent 1200 Series HPLC) was used to enrich and frac-
tionate the resuspension peptide solution. Agilent 6520
ESI Q-TOF Mass Spectrometer adopted CHIP cube as ion
source. A total of 1.0 μL sample (200 ng) was injected into
the enrich column to desalt and then analyzed online
through MSn after isocratic eluted and gradient eluted by
enrich column and separate column, respectively. Samples
of each condition were run at least in triplicate. LC-MS
and MS/MS data were processed by Spectrum Mill MS
Proteomics Workbench (Rev A.03.03.078). Protein identi-
fication was obtained through the database of UniProtKB/
SWISS-PROT especially for species of Homo sapiens. The
value of peptide spectral intensity (or peptide chromato-
graphic peak intensity, which means that MS precursor
extracted ion chromatograms intensity for peptides that
make up the same protein.) was from the analyzed data of
MS and MS/MS. The MS/MS data files for processing
were selected through the Spectrum Mill Data Extractor
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mentation spectra from raw MS/MS data files. The screen
parameters for data search were performed as previously
described [39].
Bioinformatics analysis
Modulated proteins identified by proteomic analysis
were further analysed by the PANTHER (Protein Analysis
THrough Evolutionary Relationships), a unique resource
that possible to classifies genes or proteins by their mole-
cular functions or pathways on the basis of published
papers and by evolutionary relationships (version 7.2,
http://www.pantherdb.org) [40]. The list of UniProt Ac-
cession from each protein was uploaded against the refer-
ence Homo sapiens dataset to summarize the molecular
functional and biological process.
Molecular docking study
To test the binding potency of 6-shogaol to protein
eIF2α, an excellent in silico protein-ligand docking soft-
ware for small ligand docking simulation, AutoDock 4.2
program was employed [41]. A series of steps were
applied according to the standard protocols [42]: (1)
Structure files of the target proteins were downloaded
from PDB.org in the protein data bank; (2) Unnecessary
substructures and water molecules were removed; (3)
Addition of hydrogen atoms; (4) Calculation of the
charges; (5) Run 100 times to give docked conforma-
tions; (6) Optimization of the positional, conformational,
and orientational space of the ligand. Lamarckian gen-
etic algorithm (LGA) was employed for each simulation
process. The interaction figures were generated and the
results of docking were recorded with binding energy
and bonded residue.
Murine model
Athymic nude mice (NOD/SCID, 5–6 weeks old) were
obtained from the Shanghai Laboratory Animal Center
(Shanghai, China). All animal studies were performed
according to protocols approved by the Institutional
Animal Care and Use Committee (IACUC) of the China
Pharmaceutical University. After acclimatized to their
new environment for 1 week, the mice were injected
subcutaneously with U937 cells (2.5 × 106/0.2 ml/mouse)
into the right flank (day 0). Mice were randomized into
two groups of 7 mice/group and 6-shogaol was dissolved
in 0.1% DMSO and 10% polyoxyethylene castor oil.
Three days after tumor inoculation, the treatment group
received 6-shogaol (50 mg/kg per day for 20 days) and
the control group received an equal volume of solvent
control. The tumor volume (V) was measured every three
days and calculated using the formula V = 0.5 × a × b2,
where ‘a’ and ‘b’ are the length and width of the tumor, re-
spectively. At the termination of the experiment, micewere killed at 24 h after the last administration of com-
pound. The tumors were excised, fixed in formaldehyde
and further processed for paraffin embedding.
Detection of apoptosis by TUNEL in tumor tissue sections
The apoptosis cells in the tissues were detected using
the TUNEL detection kit (In situ cell death detection
kit-POD system, Roche). Briefly, the tumor tissues of
paraffin embedded specimens were dewaxed in xylene
and rehydrated with decreasing concentrations of ethanol
[43]. Afterwards, DNA fragmentation was detected accor-
ding to the manufacturer’s instructions. For quantification,
three different fields were counted under light microscopy
and at least 500 cells were enumerated in each field. All
experiments were performed in duplicate [44].
Statistical analysis
For analysis of data, values were presented as mean ± SD
for the independent experiments. Statistical differences
were determined by non-paired Student’s two-tailed t test
and p < 0.05 was considered statistically significant.
Additional files
Additional file 1: Table S1. Identification of significantly changed
proteins in 6-shogaol treated Jurkat cells using LC-CHIP Q-TOF MS/MS.
Additional file 2: Table S2. Identification of significantly changed
proteins in 6-shogaol treated U937 cells using LC-CHIP Q-TOF MS/MS.
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